Min Jia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Min Jia has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Lirong Zhang
Department of Pharmacology, Basic Medical College, Zhengzhou University, Zhengzhou 450001, China
2 shared publications - Yanpeng Li
Shenzhen University Medical School, Shenzhen University, Shenzhen, China
2 shared publications - Jingjing Wei
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
1 shared publication - Lina Miao
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
1 shared publication - Liuding Wang
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
1 shared publication - Longtao Liu
National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
1 shared publication
Latest Publications
- 1 January 2025
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 53 (04) , 999-1026
Traditional Chinese Medicine for Cerebral Ischemia-Reperfusion Injury Prevention: Molecular Mechanisms and Future Perspectives
As reperfusion therapy becomes more common, cerebral ischemia–reperfusion (I/R) injury has emerged as a notable factor affecting the outcome of ischemic stroke. The intricate pathological mechanisms involved include oxidative stress, neuroinflammation, and various forms of cell death, characterized by interactions between multiple signaling pathways. Natural products, such as traditional Chinese medicines (TCMs), offer multi-targeted intervention effects through their diverse natural active compounds and integrate pharmacological and nutritional functions into 1 entity (Food and Medicine Homology), supporting their long-term use to prevent cerebral I/R injury. It was found that TCMs, such as Gastrodia elata Blume and Lycium barbarum L., potentially exert synergistic effects on redox imbalance, inflammation, apoptosis, and autophagy by concurrently modulating various pathways, including Nrf2/ARE, NF-κB, PI3K/Akt/mTOR, Bcl-2/Bax, and PARP-1. The prophylactic administration of TCMs may represent a novel approach for mitigating cerebral I/R injury. To advance the application of TCMs from the laboratory to clinical practice, it is essential to conduct clinical research to confirm their effectiveness and safety in preventing cerebral I/R injury.
- 1 January 2025
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 53 (04) , 999-1026
Traditional Chinese Medicine for Cerebral Ischemia-Reperfusion Injury Prevention: Molecular Mechanisms and Future Perspectives
As reperfusion therapy becomes more common, cerebral ischemia–reperfusion (I/R) injury has emerged as a notable factor affecting the outcome of ischemic stroke. The intricate pathological mechanisms involved include oxidative stress, neuroinflammation, and various forms of cell death, characterized by interactions between multiple signaling pathways. Natural products, such as traditional Chinese medicines (TCMs), offer multi-targeted intervention effects through their diverse natural active compounds and integrate pharmacological and nutritional functions into 1 entity (Food and Medicine Homology), supporting their long-term use to prevent cerebral I/R injury. It was found that TCMs, such as Gastrodia elata Blume and Lycium barbarum L., potentially exert synergistic effects on redox imbalance, inflammation, apoptosis, and autophagy by concurrently modulating various pathways, including Nrf2/ARE, NF-κB, PI3K/Akt/mTOR, Bcl-2/Bax, and PARP-1. The prophylactic administration of TCMs may represent a novel approach for mitigating cerebral I/R injury. To advance the application of TCMs from the laboratory to clinical practice, it is essential to conduct clinical research to confirm their effectiveness and safety in preventing cerebral I/R injury.
- 22 December 2012
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 69 (6) , 1269-1274
Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals
There is significant inter-individual variability in the lipid-lowering effects of atorvastatin and simvastatin. Our goal was to investigate the impact of SLCO1B1 genetic polymorphism on the lipid-lowering effects of atorvastatin and simvastatin. We recruited 363 unrelated hyperlipidemic patients with the CYP3A4*1/*1, CYP3A5*1/*1, and CYP3AP1*1/*1 genotypes: 189 of these were treated with atorvastatin and 174 were treated with simvastatin as a single-agent therapy (20 mg day−1 orally) for 4 weeks. The genotyping of SLCO1B1 c.521T > C (p.V174A, OATP-C*5) was performed with allele-specific polymerase chain reaction (AS-PCR), and PCR restriction fragment length polymorphism (RFLP) was performed to detect the carriers of SLCO1B1 c.388A > G (p.N130D, OATP-C*1b). Serum triglyceride (TGs), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels were determined before and after treatment. The frequencies of the SLCO1B1 521T > C and 388A > G variant alleles in Chinese hyperlipidemic patients were found to be 16.2% and 72.1% respectively. After treatment with 20 mg simvastatin or atorvastatin daily for 4 weeks, TC, TG, and LDL-C concentrations were lower than at baseline, on average, by 18.1 ± 3.7%, 25.8 ± 9.7%, 27.7 ± 5.4% in the simvastatin-treated group, and 17.5 ± 3.7%, 22.6 ± 8.6%, 27.5 ± 5.5% in the atorvastatin-treated group respectively, and the mean relative reduction in serum HDL cholesterol did not reach statistical significance (−1.0 ± 10.9%, 0.5 ± 9.3%). However, no significant differences were observed in the lipid-lowering effects of atorvastatin and simvastatin between subjects with different SLCO1B1 genotypes. The SLCO1B1 521T > C and 388A > G variants were found to be relatively common in Chinese patients with essential hyperlipidemia. These frequencies were found to be similar to those observed in healthy Chinese and Japanese individuals, but significantly different from Caucasians and blacks. SLCO1B1 521T > C and 388A > G polymorphisms may not be associated with the lipid-lowering effects of atorvastatin and simvastatin.
- 22 December 2012
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 69 (6) , 1269-1274
Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals
There is significant inter-individual variability in the lipid-lowering effects of atorvastatin and simvastatin. Our goal was to investigate the impact of SLCO1B1 genetic polymorphism on the lipid-lowering effects of atorvastatin and simvastatin. We recruited 363 unrelated hyperlipidemic patients with the CYP3A4*1/*1, CYP3A5*1/*1, and CYP3AP1*1/*1 genotypes: 189 of these were treated with atorvastatin and 174 were treated with simvastatin as a single-agent therapy (20 mg day−1 orally) for 4 weeks. The genotyping of SLCO1B1 c.521T > C (p.V174A, OATP-C*5) was performed with allele-specific polymerase chain reaction (AS-PCR), and PCR restriction fragment length polymorphism (RFLP) was performed to detect the carriers of SLCO1B1 c.388A > G (p.N130D, OATP-C*1b). Serum triglyceride (TGs), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels were determined before and after treatment. The frequencies of the SLCO1B1 521T > C and 388A > G variant alleles in Chinese hyperlipidemic patients were found to be 16.2% and 72.1% respectively. After treatment with 20 mg simvastatin or atorvastatin daily for 4 weeks, TC, TG, and LDL-C concentrations were lower than at baseline, on average, by 18.1 ± 3.7%, 25.8 ± 9.7%, 27.7 ± 5.4% in the simvastatin-treated group, and 17.5 ± 3.7%, 22.6 ± 8.6%, 27.5 ± 5.5% in the atorvastatin-treated group respectively, and the mean relative reduction in serum HDL cholesterol did not reach statistical significance (−1.0 ± 10.9%, 0.5 ± 9.3%). However, no significant differences were observed in the lipid-lowering effects of atorvastatin and simvastatin between subjects with different SLCO1B1 genotypes. The SLCO1B1 521T > C and 388A > G variants were found to be relatively common in Chinese patients with essential hyperlipidemia. These frequencies were found to be similar to those observed in healthy Chinese and Japanese individuals, but significantly different from Caucasians and blacks. SLCO1B1 521T > C and 388A > G polymorphisms may not be associated with the lipid-lowering effects of atorvastatin and simvastatin.
- 1 February 2011
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 51 (2) , 181-188
CYP3AP1*3Allele Is Associated With Lipid-Lowering Efficacy of Simvastatin and Atorvastatin in Chinese Women
Response to statin therapy for cardiovascular disease is variable among different individuals. The authors aimed to investigate the effect of the CYP3AP1*3 polymorphism on the lipid‐lowering efficacy of statins. They recruited 379 unrelated hyperlipidemic patients: 202 (103 men) treated with simvastatin and 177 (87 men) with atorvastatin as single‐agent therapy (20 mg day−1 orally) for 4 weeks. CYP3AP1*3(−44G>A) was genotyped using the PCR restriction fragment‐length polymorphism method. Serum levels of total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol (HDL‐C), and triglycerides (TGs) were determined before and after treatment. The frequency of the CYP3AP1*3 variant allele in Chinese hyperlipidemic patients was 70.6%. In the simvastatin treatment group, the percentage reduction of LDL‐C level was greater in the CYP3AP1*3/*3 carriers than in the CYP3AP1*1 carriers. This difference was statistically significant for women but not for men. In contrast, the authors found no significant association between the lipid‐lowering efficacy of atorvastatin and the CYP3AP1*3 polymorphism in all participants. However, in women, the percentage change of the TC level was significantly lower in the CYP3AP1*3/*3 carriers than in the CYP3AP1*1 carriers. These findings suggest that the CYP3AP1*3 allele may be a biomarker for the lipid‐lowering efficacy of simvastatin and atorvastatin in Chinese women with hyperlipidemia.
- 1 February 2011
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 51 (2) , 181-188
CYP3AP1*3Allele Is Associated With Lipid-Lowering Efficacy of Simvastatin and Atorvastatin in Chinese Women
Response to statin therapy for cardiovascular disease is variable among different individuals. The authors aimed to investigate the effect of the CYP3AP1*3 polymorphism on the lipid‐lowering efficacy of statins. They recruited 379 unrelated hyperlipidemic patients: 202 (103 men) treated with simvastatin and 177 (87 men) with atorvastatin as single‐agent therapy (20 mg day−1 orally) for 4 weeks. CYP3AP1*3(−44G>A) was genotyped using the PCR restriction fragment‐length polymorphism method. Serum levels of total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol (HDL‐C), and triglycerides (TGs) were determined before and after treatment. The frequency of the CYP3AP1*3 variant allele in Chinese hyperlipidemic patients was 70.6%. In the simvastatin treatment group, the percentage reduction of LDL‐C level was greater in the CYP3AP1*3/*3 carriers than in the CYP3AP1*1 carriers. This difference was statistically significant for women but not for men. In contrast, the authors found no significant association between the lipid‐lowering efficacy of atorvastatin and the CYP3AP1*3 polymorphism in all participants. However, in women, the percentage change of the TC level was significantly lower in the CYP3AP1*3/*3 carriers than in the CYP3AP1*1 carriers. These findings suggest that the CYP3AP1*3 allele may be a biomarker for the lipid‐lowering efficacy of simvastatin and atorvastatin in Chinese women with hyperlipidemia.